ArticleScientific reports2026
Subclinical myocardial dysfunction in treatment naive papillary thyroid carcinoma patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma (PTC) may contribute to cardiovascular (CV) morbidity through pro-inflammatory signaling and endothelial dysfunction, yet subclinical myocardial effects remain poorly characterized. While cardiovascular morbidity in papillary thyroid carcinoma (PTC) patients has largely been attributed to treatment-related factors such as TSH suppression, the potential contribution of the disease itself to early, subclinical cardiovascular vulnerability has not been well defined. To address this knowledge gap, we examined treatment-naïve PTC patients for evidence of subclinical cardiovascular dysfunction. This case-control study included 36 untreated PTC patients and 20 benign nodular goiter controls. Comprehensive cardiac assessment utilized transthoracic echocardiography, tissue Doppler imaging, and two-dimensional speckle-tracking echocardiography. Serum integrin αvβ3 and tumor necrosis factor-alpha (TNF-α) levels were quantified via enzyme-linked immunosorbent assay. Central thyroid hormone sensitivity was assessed using the Thyroid Feedback Quantile-based Index (TFQI). Compared with controls, patients with PTC exhibited evidence of subclinical myocardial functional alterations. Circulating integrin αvβ3 and TNF-α levels were significantly higher in patients with PTC. Integrin αvβ3 levels were associated with impaired GLS and diastolic dysfunction, whereas TNF-α showed no direct association with echocardiographic parameters. In addition, TFQIFT4 levels were increased in PTC group and demonstrated a positive correlation with circulating integrin αvβ3 levels, as well as an association with impaired GLS. Treatment-naive, euthyroid patients with PTC exhibit early subclinical myocardial dysfunction despite preserved ejection fraction. Impairment in GLS, derived from echocardiographic assessment, is associated with circulating integrin αvβ3 and altered central thyroid hormone sensitivity, reflecting early CV alterations that warrant confirmation in longitudinal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.